Teladoc Health (NYSE:TDOC) PT Lowered to $20.00

Teladoc Health (NYSE:TDOC) had its price target reduced by Barclays from $25.00 to $20.00 in a research note released on Friday, Benzinga reports. They currently have an overweight rating on the health services provider’s stock.

Several other analysts also recently weighed in on the stock. Piper Sandler reduced their price objective on shares of Teladoc Health from $30.00 to $25.00 and set an overweight rating for the company in a research report on Wednesday, February 21st. DA Davidson dropped their price objective on Teladoc Health from $22.00 to $18.00 and set a neutral rating on the stock in a report on Wednesday, February 21st. SVB Leerink initiated coverage on Teladoc Health in a research report on Monday, February 26th. They issued a market perform rating and a $17.00 target price for the company. Canaccord Genuity Group dropped their price target on Teladoc Health from $28.00 to $25.00 and set a buy rating on the stock in a research note on Friday. Finally, Royal Bank of Canada reduced their price objective on Teladoc Health from $30.00 to $25.00 and set an outperform rating for the company in a research note on Wednesday, February 21st. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of Hold and an average target price of $18.73.

Teladoc Health Price Performance

Teladoc Health stock opened at $13.40 on Friday. The company has a current ratio of 3.54, a quick ratio of 3.47 and a debt-to-equity ratio of 0.66. The company has a fifty day simple moving average of $14.69 and a 200-day simple moving average of $17.67. The stock has a market cap of $2.27 billion, a P/E ratio of -9.50 and a beta of 0.94. Teladoc Health has a 12-month low of $12.65 and a 12-month high of $30.41.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Thursday, April 25th. The health services provider reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.02). The business had revenue of $646.13 million for the quarter, compared to analyst estimates of $637.31 million. Teladoc Health had a negative return on equity of 10.11% and a negative net margin of 8.90%. The company’s revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.37) earnings per share. Equities analysts expect that Teladoc Health will post -1.06 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Richard J. Napolitano sold 3,765 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $54,667.80. Following the transaction, the chief accounting officer now directly owns 18,077 shares in the company, valued at $262,478.04. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Teladoc Health news, insider Laizer Kornwasser sold 7,882 shares of the stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $19.18, for a total value of $151,176.76. Following the completion of the transaction, the insider now owns 57,223 shares in the company, valued at $1,097,537.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Richard J. Napolitano sold 3,765 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $54,667.80. Following the completion of the sale, the chief accounting officer now directly owns 18,077 shares of the company’s stock, valued at approximately $262,478.04. The disclosure for this sale can be found here. In the last quarter, insiders sold 135,441 shares of company stock worth $2,038,251. 1.63% of the stock is owned by insiders.

Hedge Funds Weigh In On Teladoc Health

Large investors have recently made changes to their positions in the stock. Parallel Advisors LLC boosted its holdings in Teladoc Health by 14.6% during the fourth quarter. Parallel Advisors LLC now owns 4,038 shares of the health services provider’s stock worth $87,000 after buying an additional 515 shares in the last quarter. M&T Bank Corp lifted its position in shares of Teladoc Health by 5.5% during the 4th quarter. M&T Bank Corp now owns 11,152 shares of the health services provider’s stock valued at $241,000 after acquiring an additional 584 shares during the period. Van ECK Associates Corp lifted its position in shares of Teladoc Health by 20.3% during the 4th quarter. Van ECK Associates Corp now owns 3,589 shares of the health services provider’s stock valued at $77,000 after acquiring an additional 606 shares during the period. Arizona State Retirement System boosted its stake in shares of Teladoc Health by 1.4% during the 3rd quarter. Arizona State Retirement System now owns 46,602 shares of the health services provider’s stock worth $866,000 after acquiring an additional 650 shares in the last quarter. Finally, Victory Capital Management Inc. grew its holdings in shares of Teladoc Health by 4.3% in the 3rd quarter. Victory Capital Management Inc. now owns 17,946 shares of the health services provider’s stock worth $334,000 after acquiring an additional 748 shares during the period. Hedge funds and other institutional investors own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.